Click on headlines below to download research

Fund raising to cushion pipeline risk
Sareum Holdings | 20/08/2021

Sareum released a trading update on 19 August ahead of its full-year results (financial year end 30 June 2021) expected in October 2021. Final pre-clinical…

Edison Open House interview
Sareum Holdings - Edison Open House interview | 04/05/2021

Vivienne Parry talks to Dr. Tim Mitchell, CEO Sareum discovers and develops innovative drug candidates aimed at cancers and autoimmune diseases.

Treading the TYK2 trail
Sareum Holdings | 04/05/2021

Kinase inhibitor specialist Sareum develops small molecule therapeutics with application in oncology and autoimmune disease areas. Lead asset SDC-1801…